SuperTrans Medical
Novel Antibiotics for Targeting Resistant Bacteria
Company Overview
Snapshot
Founded in June 2019 by Eran Gilboa, SuperTrans Medical operates with 1–10 employees. The company has raised $2M across one funding round from one investor. In September 2021, SuperTrans Medical received support from the U.S. National Institutes of Health (NIH) for developing its lead antibiotic.
Business overview
SuperTrans Medical is a biopharmaceutical company focused on developing novel antibiotics to combat difficult-to-treat, multidrug-resistant bacteria, often referred to as superbugs. The company's core technology, guanidinium-rich molecular transporter (GR-MoTr), enhances the antimicrobial properties of existing FDA-approved antibiotics. SuperTrans Medical is committed to an expedited development program, serving the global biopharmaceutical and pharmaceutical markets within the Health Tech & Life Sciences sector.
Strategic signal
In September 2021, SuperTrans Medical secured support from the U.S. National Institutes of Health (NIH) for the development of its lead antibiotic targeting urgent threat drug-resistant bacteria. This endorsement from a prominent national health agency signals significant validation of the company's technology and its potential to address critical public health challenges, accelerating its path toward clinical development and market entry.
Log in to access full profile ›Company Intelligence Q&A
- What is SuperTrans Medical's primary focus?
- SuperTrans Medical is a biopharmaceutical company developing novel antibiotics to combat difficult-to-treat, multidrug-resistant bacteria, commonly known as superbugs.
- What is the core technology used by SuperTrans Medical?
- SuperTrans Medical utilizes a guanidinium-rich molecular transporter (GR-MoTr) technology, which is designed to enhance the antimicrobial properties of existing FDA-approved antibiotics.
- When was SuperTrans Medical founded?
- SuperTrans Medical was founded in June 2019.
- What was a significant development for SuperTrans Medical in September 2021?
- In September 2021, SuperTrans Medical received support from the U.S. National Institutes of Health (NIH) for the development of its lead antibiotic against drug-resistant bacteria.
- What strategic partnership did SuperTrans Medical establish in March 2021?
- In March 2021, SuperTrans Medical appointed Australian partners to provide crucial clinical research in the battle against drug-resistant bacteria.